Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which laser spot works best for glaucoma? small study tests two options

NCT ID NCT06851546

Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested two different laser treatment locations for open-angle glaucoma: one targeting the nasal side of the eye and one targeting the inferior side. 13 patients received the laser procedure to see which location better lowers eye pressure. The goal is to find the most effective spot for this common glaucoma treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Selective Laser Trabeculoplasty (SLT) procedure
What this could lead to
If successful, this could help doctors choose the best laser spot for glaucoma patients, potentially improving eye pressure control.
What could go wrong
This was a very small study (13 people) and only looked at short-term effects. Results may not apply to all glaucoma patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

13 people

The number who actually took part.

Started

Jan 2025

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years and older * Ability to comprehend the study procedures and agreement to proceed with primary SLT treatment * Diagnosis of primary or secondary open angle glaucoma or glaucoma suspects with ocular hypertension * Bilateral disease * Pre-SLT IOP \>21 mmHg measured at least twice during patient's lifetime with or without medication * Open angles with moderate to intense trabecular pigmentation * Mild to moderate visual field defects (24-2 standard mean deviations better than the Swedish interactive thresholding algorithm standard of 12 dB) * No adequate IOP control (low treatment compliance, substantial adverse effects with eyedrops, and at least 2 IOP measurements higher than the individualized target IOP) Exclusion Criteria: * Unwilling or unable to give consent * Unable to attend scheduled post-operative visits * Previous history of either laser treatment or intraocular surgery, except for non-complicated cataract surgery (performed \>6 months before SLT) * History of ocular trauma * Narrow angles * Retinal detachment * Active iris neovascularization or active proliferative retinopathy * Active uveitis * Monocular patients * Current use of steroids (ocular, periocular, or systemic)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ocular hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Open angle glaucoma

Contacts and locations

Locations

  • Eye Care Centre, Victoria General Hospital

    Halifax, Nova Scotia, NS B3H 2Y9, Canada

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.